PDS Biotech Reports Promising Results in Phase 2 Study of IL-12 Tumor Targeted Immunocytokine in Advanced Prostate Cancer

PDS Biotech announced preliminary results from a Phase 2 study of IL-12 tumor-targeted immunocytokine (PDS01ADC) in 3rd line metastatic castration-resistant prostate cancer by the NCI. The study showed a median progression-free survival of 9.6 months and a median PSA decline of 40%. PDS01ADC is an antibody drug conjugate designed to target necrotic DNA within tumors and deliver IL-12 to the tumor microenvironment.